Monitoring and evaluation
High-grade cervical lesions
- Among all diagnostic procedures, 20% are diagnosed with HSIL+, while this is the case with 66% of therapeutic procedures.
- Around 90% of women with HSIL+ biopsy have another invasive procedure (mainly therapeutic) preformed in one year period. HSIL+ is detected in almost 90% of follow-up therapeutic procedures.
- On average, 1600 women per year were newly diagnosed with CIN2+ in the past three years, 1522 in the target age group 20-64.
Table: Number of newly diagnosed CIN2+ cases by age group*
| 2017 | 2018 | 2019 | |
|---|---|---|---|
| 0-19 | 0 | 2 | 2 |
| 20-29 | 384 | 374 | 390 |
| 30-39 | 575 | 549 | 524 |
| 40-49 | 346 | 360 | 373 |
| 50-64 | 243 | 226 | 222 |
| 65+ | 76 | 67 | 86 |
| Total (20-64) | 1548 | 1509 | 1509 |
| Total (all ages) | 1624 | 1578 | 1597 |
*A newly diagnosed CIN2+ case in this table is defined as histopathologicaly confirmed CIN2+, followin a diagnostic or therapeutic invasive procedure (hysterectomies excluded), in a patient without such diagnosis in the past 3 years.
Jerman T, Ivanuš U, Florjančič M. ZORA Programme Monitoring and Evaluation. ZORA: Slovenian National Cervical Cancer Screening Programme and Registry. 2021. https://zora.onko-i.si/en/monitoring-and-evaluation/.
